A Multicenter Phase I Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma
Phase of Trial: Phase I
Latest Information Update: 08 Feb 2017
At a glance
- Drugs Ibrutinib (Primary)
- Indications Cutaneous T cell lymphoma; Peripheral T-cell lymphoma
- Focus Adverse reactions
- 02 Feb 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 28 Mar 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017 as per ClinicalTrials.gov record.
- 12 Jan 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.